Who Paid My Doc
Zevalin
Drug Oncology
NDC 72893-007-04
General payments
$66,262
Research payments
$323,272
Through program year 2024, $66,262 in general payments and $323,272 in research payments were reported against Zevalin (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $38,500 | 1 |
| 2021 | General | $482 | 33 |
| 2021 | Research | $278,772 | 1 |
| 2020 | General | $10,602 | 269 |
| 2019 | General | $55,177 | 300 |
| 2019 | Research | $6,000 | 1 |
Breakdown
The top 5 of 33 recipients; each share is of general payments naming this product in 2021.
The top 5 of 9 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
602 general · 3 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.